Versant Venture Capital VI, L.P. 13D and 13G filings for Black Diamond Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-08-08 4:48 pm Unchanged | 2024-08-06 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI, L.P. | 4,328,883 7.700% | 0 (Unchanged) | Filing |
| 2023-11-09 5:24 pm Unchanged | 2023-08-11 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI, L.P. | 4,328,883 8.400% | 0 (Unchanged) | Filing |
| 2020-12-03 4:47 pm Sale | 2020-11-23 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI, L.P. | 4,328,883 12.000% | -1,031,634 (-19.25%) | Filing |
| 2020-11-20 5:32 pm Sale | 2020-11-11 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI, L.P. | 5,360,517 14.900% | -980,734 (-15.47%) | Filing |
| 2020-09-25 4:37 pm Sale | 2020-09-17 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI, L.P. | 6,341,251 17.700% | -457,424 (-6.73%) | Filing |
| 2020-08-21 4:19 pm Sale | 2020-08-12 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI, L.P. | 6,798,675 18.900% | -669,608 (-8.97%) | Filing |
| 2020-02-13 5:23 pm Purchase | 2020-02-03 | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI, L.P. | 7,468,283 20.800% | 7,468,283 (New Position) | Filing |